What are the indications, contraindications, and follow-up protocol for Gamma Knife stereotactic radiosurgery?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 13, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Gamma Knife Stereotactic Radiosurgery

Gamma Knife stereotactic radiosurgery (GKRS) is indicated primarily for 1-4 brain metastases ≤3 cm, benign tumors (meningiomas, vestibular schwannomas, pituitary adenomas), arteriovenous malformations, and functional disorders (trigeminal neuralgia, movement disorders), with contraindications including lesions requiring immediate mass effect relief, obstructive hydrocephalus, or need for tissue diagnosis. 1, 2

Primary Indications

Brain Metastases (Most Common)

  • 1-4 lesions, each ≤3 cm in maximum diameter 1, 2
  • Can be used as monotherapy (SRS alone) or with whole brain radiation therapy (WBRT)
  • Karnofsky Performance Status ≥70 required 1
  • Local control rates: 92% at 6 months, significantly superior to WBRT alone (8% vs 100% local failure) 1

Benign Tumors

  • Meningiomas: Second most common indication 3
  • Vestibular schwannomas: First-line treatment for tumors near brainstem and cranial nerves 4
  • Pituitary adenomas
  • Glomus jugulare tumors 4

Vascular Malformations

  • Arteriovenous malformations (AVMs) 5, 3

Functional Disorders

  • Trigeminal neuralgia: 90 Gy median dose to trigeminal nerve; 82% freedom from severe pain at 24 months, 50% medication discontinuation by 3 months 6
  • Movement disorders 5, 3

Absolute Contraindications

Surgical Intervention Required Instead

  • Tumor size >3 cm - radiation necrosis risk too high, surgery preferred 2
  • Obstructive hydrocephalus or significant midline shift - requires immediate decompression 2
  • Acute mass effect with neurological deterioration - surgery resolves mass effect faster than radiosurgery 2
  • Need for tissue diagnosis - when no prior cancer diagnosis, first site of failure, or atypical imaging 2
  • Steroid-dependent symptoms - indicates significant mass effect requiring resection 2
  • Intratumoral or intracerebral hemorrhage - surgical evacuation needed 2

Relative Contraindications

  • Deep brainstem or basal ganglia lesions - unless exophytic and surgically accessible 2
  • Posterior fossa lesions with significant edema causing brainstem/fourth ventricular compression - surgery preferred for rapid decompression 2
  • Prominent cyst or necrosis - less favorable for radiosurgery 2
  • Lesions requiring ongoing anticoagulation - favors radiosurgery over surgery, but bleeding risk consideration 2

Technical Parameters

Dosing

  • Brain metastases: Single fraction 16 Gy typical; hypofractionated 27.5 Gy in 5 fractions for larger lesions 1, 7
  • Trigeminal neuralgia: 85-90 Gy to nerve 6
  • Orbital cavernous hemangioma: 12 Gy at 55-58% isodose line 8
  • Prescription isodose typically 50-60% 7

Critical Structure Dose Limits

  • Optic nerve: <12 Gy maximum 8
  • Brainstem, cranial nerves, cochlea: Proximity requires careful dose planning 4

Volume Considerations

  • Gross tumor volume ≥4.5 cc: 7-fold increased risk of symptomatic adverse radiation effects (ARE) 7
  • Larger volumes favor hypofractionation (5 fractions) over single fraction 7

Follow-Up Protocol

Imaging Surveillance

  • MRI at 6-month intervals for tumor surveillance 8
  • Sequential imaging to assess tumor response and detect radiation necrosis 8

Clinical Monitoring

  • Ophthalmological examinations every 6 months for lesions near visual pathways 8
  • Neurological examination for symptom assessment
  • Performance status monitoring (Karnofsky Performance Score) 3

Expected Outcomes Timeline

  • 3 months: 50% medication discontinuation for trigeminal neuralgia 6
  • 6 months: 70% average tumor shrinkage for benign tumors; median time to local failure with WBRT alone 1, 8
  • 12 months: 83% tumor shrinkage; 15.2% local failure rate for metastases; 10.8% ARE rate 8, 7
  • 24 months: 82% freedom from severe pain in trigeminal neuralgia 6
  • 36 months: Median time to local failure with SRS boost 1

Critical Decision Algorithm

Choose GKRS over surgery when:

  • Tumor ≤3 cm AND
  • Deep/eloquent location AND
  • Known diagnosis AND
  • No hydrocephalus/mass effect AND
  • Medical contraindications to craniotomy present 2

Choose surgery over GKRS when:

  • Tumor >3 cm OR
  • Obstructive hydrocephalus OR
  • Acute mass effect OR
  • Unknown diagnosis requiring tissue OR
  • Steroid-dependent symptoms 2

Use hypofractionated GKRS (5 fractions) when:

  • Tumor volume ≥4.5 cc to reduce symptomatic ARE risk 7
  • Total dose 27.5 Gy superior to ≤25 Gy for local control 7

Common Pitfalls

  • Treating posterior fossa lesions with significant edema: Surgery provides faster mass effect relief 2
  • Using single fraction for large volumes: Volumes ≥4.5 cc have 7-fold higher symptomatic ARE risk; use hypofractionation 7
  • Inadequate optic nerve dose planning: Keep maximum dose <12 Gy to prevent vision loss 8
  • Treating patients with KPS <70: Poor outcomes, not recommended 1
  • MRI contraindications: CT-only planning feasible for trigeminal neuralgia with comparable outcomes 6

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.